StageSeries C - II | Alive
Last Raised$50M | 2 yrs ago
About dMed Biopharmaceutical
dMed Biopharmaceuticals is a clinical development company. It provides its clients with solutions and services to improve clinical development capabilities. It was founded in 2016 and is based in Shanghai, China.
Missing: dMed Biopharmaceutical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: dMed Biopharmaceutical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing dMed Biopharmaceutical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
dMed Biopharmaceutical is included in 1 Expert Collection, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
Latest dMed Biopharmaceutical News
Dec 17, 2020
Nicole DeFeudis Associate Editor China’s cost advantage and position as the world’s second-largest prescription drug market has fueled its red-hot CRO industry over the last few years. On Thursday, Shanghai-based dMed Biopharmaceutical wrapped up a $100 million Series C round, which it says will blaze the path to an IPO. Founded in 2016 by Lingshi Tan, Pfizer’s former general manager of China R&D, dMed boasts sites in major cities across China, the US, and one location in Belgium. It hooked a $50 million Series B just last year, and opened a US regulatory affairs office in DC to help Chinese biotechs submit US filings and serve as a conduit for US drugmakers looking to outsource development to China. “A key goal in the current round is to expand our investor base to include long-term public market-focused institutions and strategic partners in order to prepare for a future IPO,” Tan said in a statement. Fidelity Management & Research led the Series C, with a helping hand from new investors Sequoia Capital China, Kaiser Foundation Hospitals and E Fund. China’s CRO market is expected to hit $27.04 billion in 2024, expanding at a compound annual growth rate of 27.06%, according to a Koncept Analytics report published earlier this year. Several factors are contributing to the growth, the report states, including increasing biologics sales, rising geriatric population, growing investment in the healthcare sector, an accelerating number of IND filings, inclining R&D expenditures and unmet need. “During previous years, the CRO industry has grown from limited clinical trial services provider to a full-service industry characterized by broad relationships with clients and service offerings that encompass the entire drug development process,” the report reads. In 2017, sweeping regulatory reforms more closely aligned China’s rules with those in the US and Europe, resulting in an influx of applications from Chinese biotechs to register drugs in the US, according to dMed. China joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), an organization that brings together regulators of the biopharmaceutical industry globally to assess the scientific and technical aspects of drug development. IND filings jumped from 11 in 2016 to 20 in 2017, with another 38 in 2018 and the first quarter of this year, dMed announced. “China is vastly different than two years ago. Government reforms and joining the ICH have helped clear the way for innovative Chinese companies to develop and launch cutting-edge therapies globally,” Tan said last year, upon announcing the DC office. “A key part of dMed’s mission is to support the globalization of drug development and help build world-class clinical, regulatory, biometrics and pharmacovigilance capabilities in China.” AUTHOR Overview The licensing of two Chimeric Antigen Receptor (CAR) T cell therapies for the treatment of B cell malignancies underscores the potential of cell based immune therapy to deliver impressive durable clinical responses¹. These products are autologous in nature which involves collecting immune cells from the patient that are used to manufacture the CAR T cells. Once produced, these CAR T cells are then reinfused as the clinical product to the patient. However, there are significant challenges to autologous therapy, including product production time (which currently takes weeks) during which the patient’s disease may progress, and the highly variable quality of the starting material, which can result in manufacturing failures. Read More December 15, 2020 05:08 PM ESTUpdated December 16, 02:18 AM Jason Mast Editor As the FDA prepared to OK the first Covid-19 vaccine last week, AstraZeneca sent instructions to its US investigators for what to do when some of their volunteers will suddenly be left to choose between staying in the British pharma’s study or receiving an FDA-authorized vaccine. The document, whose contents were described to Endpoints News by two investigators and whose existence was confirmed by another, says that investigators are allowed to individually unblind participants who become eligible for the Pfizer or Moderna vaccine and tell them which arm of the AstraZeneca study they were in. The participant can then decide whether to receive the authorized vaccine. Whichever they choose, they will be allowed to remain in the study for long-term followup. Keep reading Endpoints with a free subscription Unlock this story instantly and join 95,600+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE Jason Mast Editor At last week’s advisory committee, Pfizer executives shot down a proposal from a Stanford expert on how to keep a blinded study going even after the vaccine becomes available. On Thursday, the FDA brought the same expert back, who again argued for the blinded plan and gave an even more forceful — albeit polite — denunciation of Moderna’s plan. “This is a precedent you might not want to set,” Steven Goodman, associate dean of clinical and translational research at the Stanford University School of Medicine. Keep reading Endpoints with a free subscription Unlock this story instantly and join 95,600+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE John Carroll Editor & Founder Five years after Novartis stepped up with a sizable deal that gave them worldwide rights to Surface Oncology’s lead cancer drug, GlaxoSmithKline is coming in at the other end of the pipeline, snagging a preclinical natural killer drug designed to whip up a more effective attack on cancer cells. Unlike a lot of the preclinical collaborations we’ve seen, GSK is also freighting this with a significant amount of cash: $85 million upfront plus $730 million in milestones. And they see this new addition to the oncology pipeline as a prime candidate for future combos — all the rage these days. Keep reading Endpoints with a free subscription Unlock this story instantly and join 95,600+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE Amber Tong Senior Editor After J&J and Allergan shone a bright spotlight on the role of NMDA receptors in psychiatric diseases, Novartis has jumped in with both feet by bagging a neuroscience partner. Cadent Therapeutics is getting $210 million upfront and $560 million in milestones tied to its 3-drug pipeline — with indications spanning schizophrenia and movement disorders. “The NMDA receptor is one of the most important targets in the brain, it really controls neuronal function, I would describe it as part of the very nuts and bolts of the nervous system,” Gopi Shanker, the interim co-head of neuroscience at the Novartis Institutes for BioMedical Research, told Endpoints News. “And so modulation — the right kind of and right amount of modulation — is critical to balancing efficacy and safety and historically it’s been really difficult developing safe and effective modulators of the NMDA receptor.” Keep reading Endpoints with a free subscription Unlock this story instantly and join 95,600+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE
dMed Biopharmaceutical Frequently Asked Questions (FAQ)
When was dMed Biopharmaceutical founded?
dMed Biopharmaceutical was founded in 2016.
Where is dMed Biopharmaceutical's headquarters?
dMed Biopharmaceutical's headquarters is located at 298 Xiangke Road, 3/F, Shanghai.
What is dMed Biopharmaceutical's latest funding round?
dMed Biopharmaceutical's latest funding round is Series C - II.
How much did dMed Biopharmaceutical raise?
dMed Biopharmaceutical raised a total of $244.1M.
Who are the investors of dMed Biopharmaceutical?
Investors of dMed Biopharmaceutical include SpringHill Management, Rock Springs Capital, Superstring Capital, Qiming Venture Partners, Vivo Capital and 10 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.